updated 5/4/2011 10:16:54 AM ET 2011-05-04T14:16:54

HAMBURG, Germany, May 4, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT), (TecDAX) will report its financial results for the first quarter of 2011 on Thursday, 12 May 2011.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance:


Conference call details:
Date: Thursday, 12 May 2011
Time:
09.30 a.m. CEST
08.30 a.m. BST
03.30 a.m. US time (East Coast)
 
From Europe:
+49 (0) 6103 485 3002 (Germany)
+44-207-153-2027 (UK)
From the US: +1-480-629-9771
 
Access Code: 4435030

A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com , password: evotec0511.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49 69 58 99 90 568 (Germany) or +44 207 154 2833 (UK) and in the US by dialing +1 303 590 3030. The access code is 4435030#. The on-demand version of the webcast will be available on our website: www.evotec.com

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, MedImmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include a strategic alliance with Roche for the development of subtype-selective NMDA receptor antagonists for use in treatment-resistant depression as well as other partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes.

For additional information, please go to www.evotec.com.

CONTACT: Dr Werner Lanthaler
         Chief Executive Officer
         +49.(0)40.560 81-242
         +49.(0)40.560 81-333 Fax
         werner.lanthaler@evotec.com
         
         Evotec AG
         Schnackenburgallee 114
         22525 Hamburg (Germany)

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com